Key result
Total alkaloids of Plumula nelumbinis reduce isoproterenol-induced cardiac fibrosis in mice.
Why the study?
Plumula nelumbinis has medicinal potential, but the anticardiac fibrosis effect of its total alkaloids required evaluation.
Does total alkaloids of Plumula nelumbinis (TAP) reduce isoproterenol-induced cardiac fibrosis in mice?
Does total alkaloids of Plumula nelumbinis (TAP) reduce isoproterenol-induced cardiac fibrosis in mice?
p-value: p=< .05
Total alkaloids of Plumula nelumbinis (TAP) ameliorates isoproterenol-induced cardiac fibrosis in mice, potentially by regulating AMPK and PI3K/Akt signaling pathways to improve lipid metabolism.
Should not change clinical practice; hypothesis-generating for TAP in cardiac fibrosis, requiring human trials.
Plumula nelumbinis has great medicinal potential as a herbal tea and traditional drug in China. This study was aimed to evaluate the anticardiac fibrosis of the total alkaloids of P. nelumbinis (TAP). TAP at 50 mg/kg/day significantly ameliorated isoproterenol-induced cardiac fibrosis in mice (p < .05). The circulating lipidomics study revealed that TAP improved the lipid metabolism dysfunction in cardiac fibrosis. Meanwhile, TAP suppressed the lipid accumulation, decreased MDA level (p < .01) in heart, and increased FFA level (p < .01). Furthermore, integrating lipidomics, chemical profiles and pharmacology network analysis found that AMPK and PI3K/Akt signaling pathways were the potential targeted pathway by TAP to regulate lipid metabolism dysfunction including glycerophospholipid metabolism. Above all, TAP provided a potential anticardiac fibrosis effect partly through regulation of lipid profiles. PRACTICAL APPLICATIONS: The total alkaloids of Plumula nelumbinis (TAP) suppressed ISO-induced cardiac fibrosis in mice. Network pharmacology analysis and experiments revealed that TAP-regulated AMPK and PI3K/Akt signaling pathway to improve lipid metabolism disorder in cardiac fibrosis. This study provides evidence to the therapeutic potential of TAP in the treatment of ISO-induced cardiac fibrosis and could be a drug candidate for prevention and treatment of cardiac fibrosis.
No takes yet. Share an insight, caveat, or question.
Li et al. (2022) studied Isoproterenol-induced cardiac fibrosis. Total alkaloids of Plumula nelumbinis (TAP) was evaluated on Isoproterenol-induced cardiac fibrosis (p=< .05). Total alkaloids of Plumula nelumbinis at 50 mg/kg/day significantly ameliorated isoproterenol-induced cardiac fibrosis in mice (p < 0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: